Future drug developments in multiple myeloma: An overview of novel lenalidomide-based combination therapies

Blood Reviews

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Morgan, Gareth ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Combination therapies; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DACETUZUMAB; DEXAMETHASONE; ELOTUZUMAB; EVEROLIMUS; INTERLEUKIN 6; LENALIDOMIDE; MONOCLONAL ANTIBODY; PANOBINOSTAT; PERIFOSINE; SALINOSPORAMIDE A; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CELL CYCLE ARREST; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOPHOSPHATEMIA; IMMUNOMODULATION; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 78649714233     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(10)70006-0     Document Type: Review

References (53)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
2. Brenner H, Gondos A, Pulte D Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94:270-275.
3. Zonder AJ, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood 2007, 110. Abstract 77.
4. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
6. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
7. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001, 28:607-612.
8. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
9. Verhelle D, Corral LG, Wong K, et al. Lenaliomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
10. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
11. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
12. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
13. Noonan KA, Ferguson A, Huff CA, et al. The immunomodulatory role of lenalidomide on Prevnar® responses in patients with relapsed multiple meyloma: a comprehensive analysis of the immune response [abstract]. Blood 2008, 112. Abstract 2772.
14. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
15. Baz R, Dimopoulos M, Richardson P, Yu Z, Hussein M, Chanan-Khan A Lenalidomide-based therapy leads to improvement of humoral immune system in relapsed or refractory multiple myeloma patients who respond to the therapy [abstract]. Haematologica 2009, 94(Suppl 2). Abstract 0395.
16. Lioznov M, El-Cheikh J, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45:349-353.
17. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group Guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23:1716-1730.
18. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23:2147-2152.
19. Ishak J, Dimopoulos M, Weber D, Knight RD, Shearer A, Caro JJ Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone [abstract]. Blood 2008, 112. Abstract 3708.
20. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
21. Kröning H, Täger M, Thiel U, et al. Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol 1997, 98:116-118.
22. Bellamy WT, Richter L, Frutiger Y, Grogan TM Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
23. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
24. Otsuki T, Yamada O, Yata K, et al. Expression and production of interleukin 10 in human myeloma cell lines. Br J Haematol 2000, 111:835-842.
25. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
26. Bernal M, Garrido P, Jiménez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol 2009, 70:854-857.
27. Kim I, Uchiyama H, Chauhan D, Anderson KC Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. Br J Haematol 1994, 87:483-493.
28. Dankbar B, Padró T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95:2630-2636.
29. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87:1104-1112.
30. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
31. Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003, 63:7900-7906.
32. Siegel D, Sezer O, San Miguel JF, et al. A phase IB, multicenter, open-label, doseescalation study of oral panobinostat (LBH589) and IV bortezomib in patients with relapsed multiple myeloma [abstract]. Blood 2008, 112. Abstract 2781.
33. Siegel D, Weber DM, Mitsiades CS, et al. Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase I study [abstract]. Blood 2009, 114. Abstract 305.
34. Podar K, Chauhan D, Anderson KC Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24.
35. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
36. Richardson P, Jagannath S, Raje N, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study [abstract]. Blood 2007, 110. Abstract 187.
37. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM) [abstract]. Blood 2009, 114. Abstract 304.
38. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
39. Lonial S, Vij R, Harousseau JL, et al. Phase 1/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results [abstract]. Blood 2009, 114. Abstract 432.
40. Raje N, Richardson P, Parameswaran NH, et al. An open-label phase I study of the safety and efficacy of RAD001 in combination with lenalidomide in the treatment of patients with relapsed and relapsed/refractory multiple myeloma. Blood 2009, 114. Abstract 3856.
41. Jakubowiak A, Richardson P, Zimmermann TM, et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM) [abstract]. Blood 2008, 112. Abstract 3691.
42. Agura E, Niesvizky R, Matous J, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study [abstract]. Blood 2009, 114. Abstract 2870.
43. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
44. Richardson PG, Lonial S, Jakubowiak AJ, et al. High response rates and encouraging time-to-event data with lenalidomide, bortezomib, and dexamethsone in newly diagnosed multiple myeloma: final results of a phase I/II study [abstract]. Blood 2009, 114. Abstract 1218.
45. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
46. Vij R, Wang R, Orlowski R, et al. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update [abstract]. J Clin Oncol 2009, 27(15s). Abstract 8537.
47. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8:407-419.
48. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115:834-845.
49. Mahindra AK, Richardson PG, Hari P, et al. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma [abstract]. J Clin Oncol 2010, 28(15s). Abstract 8032.
50. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
51. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112:1329-1337.
52. van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009, 8:2616-2624.
53. Jakubowiak AJ, Benson DM, Bensinger W, et al. Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: a phase I study [abstract]. J Clin Oncol 2010, 28(15s). Abstract 8003.